Kura Oncology to Participate in Two Upcoming Investor Conferences
March 06 2019 - 6:30AM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company focused on the development of precision
medicines for oncology, today announced that Troy Wilson, Ph.D.,
J.D., President and Chief Executive Officer, is scheduled to
present at two upcoming investor conferences:
- Cowen and Company Health Care Conference in Boston on March 12,
2019 at 9:20 a.m. ET / 6:20 a.m. PT; and
- Oppenheimer Healthcare Conference in New York on March 19, 2019
at 2:10 p.m. ET / 11:10 a.m. PT.
A live audio webcast and replay of each presentation will be
available in the Investors section of Kura Oncology's website
at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The Company’s pipeline consists of small
molecule drug candidates that target cancer signaling pathways
where there is a strong scientific and clinical rationale to
improve outcomes by identifying those patients most likely to
benefit from treatment. Kura’s lead drug candidate is tipifarnib, a
farnesyl transferase inhibitor, for which the Company has initiated
a registration-directed trial of tipifarnib in recurrent or
metastatic patients with HRAS mutant HNSCC. In addition, tipifarnib
is being evaluated in multiple other Phase 2 clinical trials in
solid tumor and hematologic indications. Kura’s pipeline also
includes KO-947, an ERK inhibitor, currently in a Phase 1
dose-escalation trial, and KO-539, a menin-MLL inhibitor, which is
anticipated to enter into a Phase 1 clinical trial in the second
quarter of 2019. For additional information about Kura Oncology,
please visit the Company’s website at www.kuraoncology.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as “believes,” “anticipates,” “plans,” “expects,” “intends,”
“will,” “goal,” “potential” and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Kura Oncology’s current expectations and
involve assumptions that may never materialize, or may prove to be
incorrect. Actual results could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include, without limitation,
risks and uncertainties associated with Kura Oncology’s business
and finances in general, and the other risks described in Kura
Oncology’s periodic and other filings with the SEC. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Kura Oncology
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made
Contacts
Company:Pete De SpainVice President, Investor Relations
&Corporate Communications(858)
500-8803pete@kuraoncology.com
Investors:Robert H. UhlManaging DirectorWestwicke Partners,
LLC(858) 356-5932robert.uhl@westwicke.com
Media:Jason SparkManaging DirectorCanale Communications(619)
849-6005jason@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2023 to Apr 2024